Know Cancer

forgot password

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Phase 3
18 Years
75 Years
Open (Enrolling)

Thank you

Trial Information

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Inclusion Criteria:

- Histologically confirmed Stage IIb, IIc, III melanoma

- Surgical resection within 90 days of first dosing

- Persons with positive sentinel nodes must have a complete lymphadenectomy

- ECOG performance status 0 or 1

Exclusion Criteria:

- Any prior melanoma treatment other than surgery or regional irradiation

- Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin

- Use of biologic response modifiers within 60 days of first dosing

- Subjects with history of other malignancy within past 5 years (with exceptions)

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Recurrence Free Survival (RFS)

Outcome Time Frame:

362 events

Safety Issue:


Principal Investigator

Craig Slingluff, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Martha Jefferson Hospital, University of Virginia


United States: Food and Drug Administration

Study ID:




Start Date:

April 2012

Completion Date:

October 2018

Related Keywords:

  • Melanoma
  • Melanoma



University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Washington University School of Medicine Saint Louis, Missouri  63110
Mount Sinai School of Medicine New York, New York  10029
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Central Baptist Hospital Lexington, Kentucky  40503
City of Hope Duarte, California  91010
Mount Sinai Medical Center Miami Beach, Florida  33140
Research Across America Carrollton, Texas  75010
University of Arizona Cancer Center Tucson, Arizona  85724
Anschutz Cancer Pavilion Aurora, Colorado  
The Angeles Clinic and Research Institute Los Angeles, California  90025
Investigative Clinical Research of Indiana Indianapolis, Indiana  46254
Wake Research Associates Raleigh, North Carolina  27612
St. Louis Hospital St. Louis, Missouri  63110
Intermountain Medical Center Murray, Utah  84157
Dallas Surgical Group Dallas, Texas  75235
Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire  03756
Clinical Research Associates of Tidewater Norfolk, Virginia  23507
John Theurer Cancer Center Hackensack, New Jersey  07601
MD Anderson Cancer Center-Orlando Orlando, Florida  32806
Ameriderm Research Jacksonville, Florida  32216
Northern California Melanoma Center/ St. Mary's Medical Center San Francisco, California  94117
The Melanoma Center at the Washington Cancer Institute Washington, District of Columbia  20010
Oncology Specialists, SC (OSSC) Niles, Illinois  60714
Central Kentucky Research Associates Lexington, Kentucky  40509
Center for Pharmaceutical Research Kansas City, Missouri  64114
Wake Forest University School of Medicine, Comprehensive Cancer Center Winston-Salem, North Carolina  27157
Kimmel Cancer Center at Thomas Jefferson Univ. Philadelphia, Pennsylvania  19107
The Huntsman Cancer Institute, University of Utah Salt Lake City, Utah  84112-5550
Arizona Clinical Research Tucson, Arizona  85715
Pacific Dermatology Institute Temecula, California  92592
University of Minnesota Masonic Cancer Institute Minneapolis, Minnesota  55455
Mayo Clinic Cancer Center, Mayo Clinic Rochester Rochester, Minnesota  55905
Cancer Center of NJ New Brunswick, New Jersey  08901
University of Virginia Hospital Charlottesville, Virginia  22908